Tuesday, August 23, 2011 (Last Updated: 08/24/2011)
TUESDAY, Aug. 23 (HealthDay News) -- In patients with postmenopausal breast cancer, elevated pre-treatment serum beta C-terminal telopeptide (B-CTx) levels are significantly associated with shorter recurrence-free survival (RFS) for bone-only metastases, according to a study published online Aug. 22 in the Journal of Clinical Oncology.
Allan Lipton, M.D., from the Penn State Hershey Medical Center in Pennsylvania, and colleagues investigated the association of bone-only relapse with pretreatment serum B-CTx of type 1 collagen in 621 patients with primary breast cancer, enrolled in a phase III adjuvant trial of tamoxifen with or without octreotide. Continuous or categorical serum B-CTx was analyzed (0.71 ng/mL cut point) in a stepwise forward multivariate Cox regression model, and adjusted for trial stratification factors. B-CTx and bone-relapse were examined by pretrial chemotherapy status. Participants were followed up for an average of 7.9 years. Bone-only relapse and RFS were primary and secondary endpoints, respectively.
The investigators found that 123, 19, and 47 patients experienced recurrence, bone-only recurrence, and bone plus other sites of recurrences, respectively. When added to a model with factors significant in the main trial analyses, elevated continuous and categorical serum B-CTx, and larger pathologic tumor sizes were significantly correlated with shorter bone-only RFS (hazard ratio, 3.50 and 3.43, respectively). Serum B-CTx levels did not correlate with any other type of recurrence, and its level in patients who underwent pretrial chemotherapy was not significantly different from those who did not. The pretrial chemotherapy had no effect on bone relapse.
"Higher pretreatment serum B-CTx was a significant predictor of shorter RFS for bone-only metastasis," the authors write.
Several of the study authors disclosed financial ties with the pharmaceutical industry.
Hematology & Oncology
Copyright © 2011 HealthDay. All rights reserved.